Tags » Hemophilia A

Bayer’s Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

In the PROTECT VIII study, BAY94-9027 met its primary efficacy and safety objectives for the treatment of patients with hemophilia A / Extending infusion intervals up to seven days resulted in protection from bleeds comparable to current prophylactic dose regimens / No patient developed inhibitors to factor VIII during the 36-week treatment period. 1,022 more words